Prescription medicine
Sucralfate Brand names: Carafate
Sucralfate (Carafate) is a prescription medicine with an FDA approval on record since 1981. FDA's NDC Directory lists it from 43 generic labelers, and pharmacies paid $0.173 per sucralfate 1 g tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the sucralfate FDA label on DailyMed (effective September 2, 2026, Preferred Pharmaceuticals Inc.); the NDA 18333 record on Drugs@FDA; every sucralfate label on DailyMed.
Highlights of the record
FDA label of September 2, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSucralfate is indicated in:
Short-term treatment (up to 8 weeks) of active duodenal ulcer.
Forms and strengths
- 1 g
- 1 g/10ml
Tablet; suspension.
On the market
- Earliest approval on file
- October 30, 1981 Carafate, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 14 first March 29, 1996; 13 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 46 of which 43 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.173 per tablet Sucralfate 1 g tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 6 since 2022 1 Class I among all firms' recalls; latest October 9, 2025
- FAERS reports
- 23,820 through July 30, 2026
What is sucralfate used for?
From the label: indications and usageSucralfate is indicated in:
Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Conditions named in the indications of sucralfate's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Aluminum Complex.
Source: FDA drug label (Sucralfate), NDA018333 (Abbvie), as published by Preferred Pharmaceuticals Inc., effective September 2, 2026 (SPL set 536b8c00-13ab-4397-a754-63a1c92bf883), via openFDA; the full label on DailyMed
Is there a generic for sucralfate (Carafate)?
The FDA approved the first generic sucralfate on March 29, 1996. 14 generic applications are approved; 13 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists sucralfate from 43 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1981 earliest approval on file
- 1996 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for sucralfate (Carafate)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.173 per Sucralfate 1 g tablet, down 6% from $0.183 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Sucralfate 1 g tablet (generic)
- Carafate 1 g tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Sucralfate 1 g tablet | Generic | $0.173 per tablet | $5.18 | -6% |
| Sucralfate 1 g/10 mL suspension | Generic | $0.124 per mL | n/a | +1% |
| Carafate 1 g tablet | Brand | $4.73 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $141.92 | -0.3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has sucralfate been recalled?
The FDA's Enforcement Report lists 6 recalls naming sucralfate since 2022: 1 Class I (the most serious), 5 Class II, 0 Class III; 3 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| October 9, 2025 | Class II | Amerisource Health Services LLC | CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that … |
| July 29, 2025 | Class II | Amerisource Health Services LLC | CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that … |
| July 11, 2025 | Class II | Nostrum Laboratories, Inc. | CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that … |
| October 18, 2023 | Class I | VistaPharm LLC | Microbial Contamination of Non-Sterile Products: identified as Bacillus cereus. |
| August 30, 2023 | Class II | VistaPharm LLC | Superpotent/Subpotent single ingredient Drug: Out of Specification Assay results |
| March 11, 2022 | Class II | DASH Pharmaceuticals LLC | Labeling: Label Mix-Up |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the sucralfate label say about other medicines?
The sucralfate label names 11 other medicines in its interaction, contraindication or warning sections. The labels of 22 other medicines name sucralfate. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cimetidine | drug interactions | Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline … |
| Ciprofloxacin | drug interactions | In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. |
| Digoxin | drug interactions | Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline … |
| Ketoconazole | drug interactions | Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline … |
| Ofloxacin | drug interactions | In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. |
| Phenytoin | drug interactions | Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline … |
| Quinidine | drug interactions | … of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. |
| Ranitidine | drug interactions | … following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. |
| Tetracycline | drug interactions | … cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. |
| Theophylline | drug interactions | … fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. |
| Warfarin | drug interactions | However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. |
Other labels that name sucralfate
- Aminophylline
- Bictegravir and emtricitabine and tenofovir alafenamide
- Bictegravir and lenacapavir
- Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide
- Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil
- Dolutegravir
- Furosemide
- Lansoprazole
- Levoketoconazole
- Levothyroxine
- Moxifloxacin
- Naproxen
Source: FDA drug label (Sucralfate), NDA018333 (Abbvie), as published by Preferred Pharmaceuticals Inc., effective September 2, 2026 (SPL set 536b8c00-13ab-4397-a754-63a1c92bf883), via openFDA; the full label on DailyMed
What do FAERS reports show for sucralfate?
The FDA Adverse Event Reporting System holds 23,820 reports that list sucralfate among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,309 are coded as a death and 9,251 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as sucralfate?
21 other medicines are given the same way (oral) and in the same FDA class as sucralfate or labeled mainly for the same use (acid reflux and ulcers), the same class first. Acid reflux and ulcers lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Calcium carbonate | Acid reflux and ulcers | none listed | $0.0315 per tablet 750 mg tablet chewable | No current entry |
| Omeprazole | Acid reflux and ulcers | 121 labelers | $0.0295 per capsule 20 mg capsule | A presentation being discontinued |
| Famotidine | Acid reflux and ulcers | 144 labelers | $0.0289 per tablet 20 mg tablet | No current entry |
| Esomeprazole | Acid reflux and ulcers | 117 labelers | $0.145 per capsule 20 mg capsule | No current entry |
| Pantoprazole | Acid reflux and ulcers | 52 labelers | $0.0358 per tablet 40 mg tablet | No current entry |
| Lansoprazole | Acid reflux and ulcers | 59 labelers | $0.106 per capsule 30 mg capsule | No current entry |
| Metoclopramide | Acid reflux and ulcers | 28 labelers | $0.0439 per tablet 10 mg tablet | No current entry |
| Calcium carbonate and famotidine and magnesium hydroxide | Acid reflux and ulcers | 20 labelers | $0.258 per tablet Acid reducer complete tablet chewable | No current entry |
Every medicine labeled for the same conditions as sucralfate
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does sucralfate compare with medicines for the same use?
7 side-by-side pages set sucralfate beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to sucralfate
- 21 medicines for the same use
- Sucralfate side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other